Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197638 | 0.92 | CA1 (0.47) | NAMPTCA1CA2CA9HPGDS | |
| SCHEMBL15739735 | 0.90 | CA1 (0.49) | CA1CA2CA9NPC1RAB9A | |
| SCHEMBL103893 | 0.87 | CA1 (0.51) | CA1CA2CA9NPC1RAB9A | |
| SCHEMBL4112154 | 0.84 | NPC1 (0.56) | CA1CA2CA9NPC1RAB9A | |
| SCHEMBL1962378 | 0.83 | NPC1 (0.58) | CA1CA2CA9NPC1RAB9A | |
| SCHEMBL26087371 | 0.82 | CA1 (0.47) | CA1CA2CA9HPGDSNPC1 | |
| SCHEMBL26087369 | 0.82 | CA1 (0.47) | CA1CA2CA9HPGDSNPC1 | |
| SCHEMBL1989732 | 0.80 | HDAC4 (0.48) | CA1CA2CA9NPC1RAB9A | |
| SCHEMBL30326431 | 0.80 | CA1 (0.47) | CA1CA2CA9KMT2A | |
| SCHEMBL25288985 | 0.78 | HPGDS (0.51) | CA1CA2CA9HPGDSUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2538784-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2015-09-09 | — | — | EP | disclosed |
| US-8895596-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2538784-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309736-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DONME CORP | 2012-12-06 | — | — | US | disclosed |
| WO-2011106273-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309736-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | NAMPT 522/4885CA1 4864/4885CA2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.